Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo

類似資料

• PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
  著者:: Black, Jonathan D, 等
  出版事項: (2015)
• PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
  著者:: Black, Jonathan D, 等
  出版事項: (2015)
• Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo
  著者:: Lopez, Salvatore, 等
  出版事項: (2015)
• Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
  著者:: Cocco, Emiliano, 等
  出版事項: (2016)
• Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
  著者:: Schwab, C L, 等
  出版事項: (2014)